Compare CACC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CACC | LNTH |
|---|---|---|
| Founded | 1972 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.4B |
| IPO Year | 1992 | 2015 |
| Metric | CACC | LNTH |
|---|---|---|
| Price | $475.59 | $67.47 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $465.00 | $78.00 |
| AVG Volume (30 Days) | 124.0K | ★ 1.1M |
| Earning Date | 01-29-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.44 | N/A |
| EPS | ★ 37.89 | 2.39 |
| Revenue | $1,232,900,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | $129.15 | $0.01 |
| Revenue Next Year | $1.97 | $0.52 |
| P/E Ratio | ★ $12.57 | $28.23 |
| Revenue Growth | ★ 45.72 | 1.95 |
| 52 Week Low | $401.90 | $47.25 |
| 52 Week High | $560.00 | $111.29 |
| Indicator | CACC | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 61.85 |
| Support Level | $450.53 | $66.36 |
| Resistance Level | $483.72 | $70.33 |
| Average True Range (ATR) | 13.34 | 1.67 |
| MACD | 1.52 | -0.20 |
| Stochastic Oscillator | 83.61 | 60.37 |
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.